Astria Therapeutics (ATXS) News Today $7.50 -0.25 (-3.23%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short InterestAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 15th total of 2,680,000 shares. Currently, 7.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 286,800 shares, the short-interest ratio is presently 11.8 days.January 16 at 11:58 PM | marketbeat.comHead-To-Head Contrast: Astria Therapeutics (NASDAQ:ATXS) and RedHill Biopharma (NASDAQ:RDHL)January 15 at 1:41 AM | americanbankingnews.comAstria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAEJanuary 14, 2025 | finance.yahoo.comAstria Therapeutics (NASDAQ:ATXS) Given "Buy" Rating at HC WainwrightJanuary 14, 2025 | americanbankingnews.comAstria Therapeutics designs ALPHA-ORBIT Phase 3 trial of navenibart in HAEJanuary 14, 2025 | markets.businessinsider.comOptimistic Buy Rating for Astria Therapeutics Driven by Promising Phase 3 ALPHA-ORBIT TrialJanuary 14, 2025 | markets.businessinsider.comAstria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of "Buy" by AnalystsJanuary 13, 2025 | americanbankingnews.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by BrokeragesShares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have earned a consensus rating of "Buy" from the six analysts that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned aJanuary 13, 2025 | marketbeat.comJane Street Group LLC Has $404,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)Jane Street Group LLC reduced its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 67.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,736 shares of the biotechnology company's stock afterJanuary 8, 2025 | marketbeat.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | businesswire.comGeode Capital Management LLC Trims Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS)Geode Capital Management LLC cut its position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 6.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 953,167 shares of the biJanuary 1, 2025 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest UpdateAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,680,000 shares, a decline of 14.9% from the November 30th total of 3,150,000 shares. Approximately 5.6% of the shares of the company are sold short. Based on an average daily trading volume, of 329,100 shares, the days-to-cover ratio is presently 8.1 days.December 29, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 3.4% - Here's What HappenedAstria Therapeutics (NASDAQ:ATXS) Shares Down 3.4% - Should You Sell?December 26, 2024 | marketbeat.comState Street Corp Reduces Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)State Street Corp cut its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 24.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,556,283 shares of the biotechnology company's stock after sellingDecember 25, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock, Short Interest ReportDecember 23, 2024 | benzinga.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The instiDecember 21, 2024 | marketbeat.comAstria Therapeutics Expands Stock Incentive PlanDecember 19, 2024 | tipranks.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from BrokeragesShares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has issued a strDecember 19, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Growth in Short InterestAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 3,150,000 shares, an increase of 8.6% from the November 15th total of 2,900,000 shares. Based on an average daily volume of 321,400 shares, the short-interest ratio is presently 9.8 days. Approximately 6.5% of the company's stock are short sold.December 15, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 152.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 314,265 shares of the bioDecember 15, 2024 | marketbeat.comAstria Therapeutics’ Navenibart Shows Promising Results in HAE Prophylaxis, Earning Buy RatingDecember 12, 2024 | markets.businessinsider.comAstria Therapeutics price target raised to $32 from $28 at OppenheimerDecember 12, 2024 | markets.businessinsider.comAstria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAEDecember 11, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Fmr LLCFmr LLC raised its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 29.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,822,275 shares of the biotechnology company's stock afterDecember 6, 2024 | marketbeat.comRA Capital Management L.P. Has $56.21 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)RA Capital Management L.P. increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 1.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,105,213 shares of the biotechnology company's stocDecember 5, 2024 | marketbeat.comRedmile Group LLC Takes $3.42 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)Redmile Group LLC purchased a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the third quarter, according to its most recent filing with the SEC. The fund purchased 310,884 shares of the biotechnology company's stock, valued at approximately $3,423,000. Redmile Group LLC owneDecember 5, 2024 | marketbeat.comWalleye Capital LLC Buys 71,439 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Walleye Capital LLC raised its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 69.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 174,581 shares of the biotechnology company'sDecember 5, 2024 | marketbeat.comVestal Point Capital LP Acquires 750,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Vestal Point Capital LP grew its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 23.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,000,000 shares of the biotechnology company's stock after acquiring an additional 750,000 shareNovember 29, 2024 | marketbeat.comAstria Therapeutics: Transformative Proof Of Concept Data In Hereditary AngioedemaNovember 27, 2024 | seekingalpha.comResearch Analysts Set Expectations for ATXS FY2024 EarningsAstria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Astria Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology cNovember 18, 2024 | marketbeat.comAstria Therapeutics Reports Q3 2024 Financial ResultsNovember 16, 2024 | tipranks.comAstria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 15, 2024 | stockhouse.comAstria Therapeutics (NASDAQ:ATXS) Shares Down 5.3% - Time to Sell?Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3% - What's Next?November 15, 2024 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)November 14, 2024 | markets.businessinsider.comPromising Outlook for Astria Therapeutics: Strong Financials and Key Program Advancements Support Buy RatingNovember 14, 2024 | markets.businessinsider.comOppenheimer Remains a Buy on Astria Therapeutics (ATXS)November 14, 2024 | markets.businessinsider.comAstria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst UpgradeAstria Therapeutics (NASDAQ:ATXS) Shares Gap Up After Analyst UpgradeNovember 14, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 at OppenheimerOppenheimer boosted their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Thursday.November 14, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Cross Above 50-Day Moving Average - What's Next?Astria Therapeutics (NASDAQ:ATXS) Shares Cross Above 50 Day Moving Average - Here's WhyNovember 7, 2024 | marketbeat.comAstria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific MeetingOctober 30, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from AnalystsAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and one has given a stronOctober 30, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Up 6.8% - Should You Buy?Astria Therapeutics (NASDAQ:ATXS) Trading 6.8% Higher - Here's WhyOctober 24, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Passes Below 50 Day Moving Average - Should You Sell?Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Below 50-Day Moving Average - Should You Sell?October 23, 2024 | marketbeat.comAstria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific MeetingOctober 21, 2024 | finance.yahoo.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1% - Should You Sell?Astria Therapeutics (NASDAQ:ATXS) Shares Down 4.1% - What's Next?October 14, 2024 | marketbeat.comDimensional Fund Advisors LP Acquires 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Dimensional Fund Advisors LP raised its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 1,043.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 146,158 shares of the biotechnologyOctober 13, 2024 | marketbeat.comCubist Systematic Strategies LLC Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS)Cubist Systematic Strategies LLC purchased a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 281,410 shares of the biotechnology company's stock, valued at approximately $2,October 12, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Up 5.2% - Here's What HappenedAstria Therapeutics (NASDAQ:ATXS) Stock Price Up 5.2% - Should You Buy?October 11, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Millennium Management LLCMillennium Management LLC increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 13.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,842,063 shares of the biotechnologOctober 6, 2024 | marketbeat.com Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXS Media Mentions By Week ATXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATXS News Sentiment▼0.460.57▲Average Medical News Sentiment ATXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATXS Articles This Week▼113▲ATXS Articles Average Week Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Galapagos News Today Arcutis Biotherapeutics News Today Indivior News Today Akero Therapeutics News Today Dyne Therapeutics News Today Immunocore News Today Evotec News Today Travere Therapeutics News Today Vir Biotechnology News Today Structure Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATXS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXS Stock Alerts